Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen
H Jorn
HJ
Gerritsen
Wil-Janne
WJ
de Jong
Elke M G J
EM
van de Kerkhof
Peter C M
PC
D000279:Administration, Cutaneous; D000077944:Alefacept; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007273:Injections, Intramuscular; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D011993:Recombinant Fusion Proteins; D001623:Betamethasone; D000077944:Alefacept